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Abstract
Background. Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients
although the actual prevalence, phenomenology and risk factors remain unclear. The aim of
the present study was to address the three aforementioned questions.
Methods. The electronic records of a large cohort of clozapine-medicated schizophrenia patients
routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version
(OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined.
Results. OCD prevalence was 47%, higher in patients on poly-pharmacy than on monother-
apy (64% vs 31%; p = 0.001). Two OCI-R factors had significantly higher scores and distinct
risk factors: checking behaviour (mean = 5.1; SD = 3.6) correlated with length of clozapine
treatment (r = 0.21; p = 0.026), and obsessing factor (mean = 4.8; SD = 3.6) correlated
with psychosis severity (r = 0.59; p = 0.001). These factors along with total OCI-R, did not
correlate with either clozapine dose or plasma levels, after correcting for psychosis severity.
Conclusions. Screening for OCD in clozapine patients, and probably in those treated with
structurally similar drugs with potent antiserotoninergic properties, should be widely adopted
by clinicians. Further research is needed to understand the pathophysiology underlying repeti-
tive behavior onset in clozapine-treated patients.
Background
Obsessive–compulsive disorder (OCD) is common in schizophrenia patients treated with anti-
psychotics with significant anti-serotoninergic action (Swets et al. 2014; Grillault Laroche &
Gaillard, 2016). Clozapine was the first drug reported (Baker et al. 1992) and is still the medi-
cation more frequently associated with OCD (Poyurovsky et al. 2001), along with olanzapine
(Schirmbeck et al. 2011). However, the prevalence, phenomenology and pathophysiology of
clozapine-induced OCD remain unclear.
In the literature, the prevalence of clozapine-induced OCD ranges from <5% (Mahendran et al.
2007) to over 70% (Schirmbeck et al. 2011). This discrepancy reflects the heterogeneity in themeth-
odology used, such as the diagnostic instrument (structured clinical interview v. scale score thresh-
old) and the sample characteristics, among others. For instance, some studies only included patients
on clozapine monotherapy (Lin et al. 2006; Schirmbeck et al. 2011), whereas others broaden the
scope to cases using concomitant medication (Poyurovsky et al. 2001; Mukhopadhaya et al.
2009). Noteworthy, medications like antidepressants or antipsychotics are also prescribed for treat-
ing OCD and therefore could potentially mask OCD prevalence and severity.
From the point of view of phenomenology, degree of insight should help to distinguish
between delusions and obsessions (Poyurovsky et al. 2004), but this can be difficult to disentan-
gle in the presence of chronic positive symptoms in clinical practice (Leung & Palmer, 2016).
Most studies of prevalence have not taken into account psychosis severity (Poyurovsky et al.
2001; Lin et al. 2006; Faragian et al. 2009; Mukhopadhaya et al. 2009). When psychosis is con-
sidered, most (Guillem et al. 2009; Sa et al. 2009) but not all (Faragian et al. 2009) studies have
associated delusions and OCD severity, which suggests an overlap between them. Clinically, a
predominantly compulsion profile was initially described in clozapine-associated OCD
(Ongür & Goff, 2005; Guillem et al. 2009; Kim et al. 2012), but this has not always been repli-
cated (Schirmbeck et al. 2011; Doyle et al. 2014). The type of compulsion also varies across stud-
ies, as the predominance of checking (Poyurovsky et al. 2004; Mukhopadhaya et al. 2009;
Schirmbeck et al. 2011) and also cleaning and washing (Poyurovsky et al. 2001; Faragian
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et al. 2009; Guillem et al. 2009) compulsions have been reported.
Nevertheless, there is a high concordance of the obsession–com-
pulsion pair: contamination with washing (Poyurovsky et al.
2001; Ongür & Goff, 2005; Faragian et al. 2009; Sa et al. 2009)
and doubting with checking (Leung & Palmer, 2016).
Length of clozapine treatment is a replicated risk factor for
developing OCD (Lin et al. 2006; Boyette et al. 2011; Schirmbeck
et al. 2011; Scheltema Beduin et al. 2012). However, the evidence
for OCD being a clozapine dose-dependent side effect is still incon-
clusive. For instance, one study found that patients with
clozapine-associated OCD were treated with higher drug doses
(Mukhopadhaya et al. 2009), and another study (Schirmbeck
et al. 2011) showed a correlation between dose and OCD symptoms
but failed to correlate with clozapine plasma levels. Noteworthy,
plasma level is considered as a more accurate measure, as it is
not affected by patients’ compliance or pharmacokinetic factors
(i.e. smoking). To date, no study has found a correlation between
clozapine plasma levels and obsessive and compulsive symptom
(OCS) severity (Lin et al. 2006; Schirmbeck et al. 2011).
Aims of the study
The aims of this study was to address three aforementioned ques-
tions of OCD prevalence, clinical profile and associated severity
factors, using electronic records of a large cohort of clozapine-
medicated schizophrenic patients. Patients were routinely
screened for OCD using standardised scales as well as relevant
clinical, psychometric and demographic data.
Material and methods
Study design
This is a cross-sectional, single-centre study of a cohort of
clozapine-treated schizophrenia patients at the Cambridgeshire
and Peterborough NHS Foundation Trust, a community mental
health trust in the UK. The study included electronic clinical
records of more than 200 cases from August 2015 to June 2017.
The anonymised clinical records were embedded in an ethically
approved database for research and clinical purposes (13/EE/
0121). All cases were reviewed by the same care consultant (EFE).
Study sample
All records of clozapine-treated schizophrenia cases were initially
included, regardless of other medication status. The only exclusion
criterion was not suffering with a primary psychotic disorder (i.e.
off label use of clozapine). All cases were included for the prevalence
and phenomenology analyses. Stricter criteria were defined for the
analysis of the role of clozapine dose and plasma level onOCD sever-
ity, i.e: only cases on clozapine monotherapy, with clozapine plasma
levels available and with evidence of adequate medication compli-
ance measured by the clozapine:norclozapine ratio, were included.
Clinical assessment
Assessment includes full psychiatric history, mental state examin-
ation, current medication list, smoking, legal and illegal drugs
habits, comprehensive clozapine side effects assessment, physical
health assessment and psychopathological scales (see below),
among others. Per protocol, clozapine and norclozapine plasma
levels are assessed every 3 years, unless otherwise required for
clinical reasons (i.e. change in smoking status, side effects or com-
pliance queries). Levels were determined at the Toxicology
Department, King’s College Hospital, London, UK.
Psychopathological scales
All assessment included Global Assessment of Functioning (GAF)
and Clinical Global Impression for Schizophrenia (Haro et al.
2003), which measures severity of positive, negative, depressive,
cognitive symptoms domains as well as an overall score, all ran-
ging from 1 (no symptoms) to 7 (extremely severe). The Short
version of the Warwick-Edinburg Wellbeing scale was performed
annually (Brown et al. 2016).
Since August 2015, the Obsessive Compulsory Inventory-Revised
(OCI-R) (Foa et al. 2002) was added to the routine assessment while
subjects were doing the routine plasma level control, in order to
screen subjectswith obsessive symptoms thatmight require interven-
tion. OCI-R is a widely used 18-item self-rated questionnaire easy to
implement in clinical settings. Each question has a five-point
Likert-type score that measures the degree of distress or being both-
ered with commonOCD phenomena, ranging from 0 (‘not at all’) to
4 (‘extremely’). The cut-off point forOCDdiagnosis is 21 for the total
OCI-R.The scale is composedof six factors of three items each, evalu-
ating washing behaviour, obsessing thinking, hoarding, ordering,
checking behaviour and mental neutralisation. For OCD diagnosis,
a cut-off point for the obsessive factor of 5 has been defined (Foa
et al. 2002). As there are no specific cut-off points for the other five
factors, herewehaveused the same five-point cut-off forclinicallysig-
nificant symptoms to reach the disorder threshold.
Concomitant medication assessment
Poly-pharmacy is common in treatment-resistant schizophrenia.
Some of these drugs can potentially influence obsessive symptoms.
For instance, clozapine augmentation with aripiprazole is common
for persistent psychotic symptoms (Cardinal et al. 2015) but can
also be added as therapy for OCD (Englisch et al. 2009; Eryılmaz
et al. 2013), sedation (Perdigués et al. 2016) or metabolic
complications (Zimbron et al. 2016). Similarly, antidepressants
are primarily used for depression, anxiety or OCD. Rather than
excluding cases on poly-pharmacy, we adopted a pragmatic
approach by recording dichotomic (yes/no) variable for medica-
tion use, regardless of the primary indication: use of any drug
with potential effect on OCD (aripiprazole, selective serotoninergic
reuptake inhibitor, SSNRI or tricyclics), which for simplification in
this manuscript we termed as anti-OCD medication.
Statistical analysis
All statistical analyses were conducted using SPSS v23.0 for Mac,
with a two-tail 0.05 significance level. As described in the Results
section, χ2, Student’s t test, analysis of variance and bivariate cor-
relation using Pearson r coefficient were used according to the
analysis needs. Partial correlation was used for controlling the
role of a third factor on bivariate correlations. An exploratory fac-
tor analysis was also carried out to compare our data structure
with the six-factor component of the OCI-R.
Results
Two hundred and one patients on clozapine and with primary
diagnosis of non-affective psychosis were included. Of those,
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122 (60.7%) completed the OCI-R scale during the clinical review.
Three patients were excluded from the analyses as OCD predated
psychosis (two cases) and another case due to lack of reliability in
the answers, reaching a final sample of 118 cases.
Prevalence of OCD
Among the 118 cases, the mean OCI-R total score was 20.3
(S.D. = 13.7) and 47% (n = 55) reached threshold criteria for OCD.
Fifty-five of the 118 cases (47%) were on anti-OCD medication.
As shown in Table 1, patients on poly-pharmacy had significantly
higher OCI-R scores (24.6 S.D. = 13.2 v. 16.2 S.D. = 12.2; t = 3.465;
p = 0.001) and OCD prevalence (64% v. 31%; χ2 = 12.001; p =
0.001) as well as higher clinical global impression (CGI)-positive
scores (3.1 S.D. = 1.6 v. 2.5 S.D. = 1.5; t = 2.184; p = 0.031).
OCS profile
We tested if our OCI-R responses fit the original OCI-R factor
structure, as its validity has not been formally tested before in
schizophrenia patients. To this aim, we used an exploratory factor
analysis of the individual answers, fixing a six-factor model and
choosing a maximum likelihood as extraction method with no
rotation. A χ2 measure of goodness-of-fit, testing the null hypoth-
esis that six factors were adequate to explain 76% of the
co-variances in our data, showed a χ2 = 112.67, with a p < 0.001.
Mean scores of the six factors were (from higher to lower):
checking 5.1 (S.D. = 3.6); obsessing 4.8 (S.D. = 3.6); hoarding 3.2
(S.D. = 3.2); ordering 2.9 (S.D. = 3.0); neutralising 2.4 (S.D. = 3.0)
and washing 1.8 (S.D. = 2.4). All six factors showed significant
greater severity in the poly-medicated group (Table 2). When a cut-
off point of 5 was applied to indicate ‘disorder’, about half of
patients reported significantly distressing checking compulsions
and obsessive thinking (Fig. 1). In order to improve readability,
we will report here only checking and obsessing factors, although
online Supplementary Table shows analyses with all six factors.
Role of severity of schizophrenia-positive symptoms in OCS
OCI-R is a self-rated questionnaire and some questions illustrate
the overlap of obsessive and psychotic phenomena. For instance,
question 6 (obsessing factor) states: ‘I find difficult to control my
Table 1. Samples sociodemographic and clinical variables, expressed as mean and standard deviation
Total sample Monotherapy Poly-therapy p
N 118 63 55
Gender male n (%) 98 (83%) 54 (85.7%) 44 (80.0%) 0.28
Age (in years) 44.3 (11.0) 43.3 (12.1) 45.5 (9.7) 0.29
Clozapine treatment (in years) 14.6 (7.1) 14.6 (7.4) 14.5 (6.8) 0.93
Clozapine dose (mg/day) 346 (141) 337.1 (144.7) 356.8 (138.3) 0.45
Clozapine plasma level (mg/dL) 0.42 (0.22) 0.39 (0.22) 0.45 (0.23) 0.20
Norclozapine plasma levels (mg/dL) 0.27 (0.13) 0.26 (0.13) 0.29 (0.13) 0.28
GAF score 70.1 (12.9) 71.5 (14.0) 68.4 (11.4) 0.19
CGI-positive 2.8 (1.6) 2.51 (1.5) 3.13 (1.6) 0.03
CGI-negative 3.0 (1.3) 2.98 (1.4) 3.09 (1.2) 0.65
CGI-overall 2.7 (1.0) 3.27 (1.3) 3.67 (1.0) 0.22
On aripiprazole 24% 51%
On antidepressants (SSRI/SNRI) 33% 71%
p represents p-significance group differences (monotherapy v. poly-therapy) using Student’s t or χ2 tests.
SSRI, selective serotoninergic reuptake inhibitor (fluoxetine, paroxetine, fluvoxamine, citalopram, sertraline and escitalopram); SNRI, serotonin and norepinephrine reuptake inhibitors
(venlafaxine and duloxetine).
Table 2. Mean score and standard deviation (S.D.) of the OCI-R total and six factors
Total sample Monotherapy Polypharmacy p significance
Sample size 118 63 55
OCI-R total score 20.3 (13.7) 16.5 (12.2) 24.6 (13.2) 0.001
Checking factor 5.1 (3.6) 4.3 (3.4) 5.8 (3.6) 0.018
Obsessing factor 4.8 (3.6) 3.4 (3.1) 6.5 (3.5) <0.001
Hoarding factor 3.2 (2.8) 2.4 (2.5) 4.1 (2.9) 0.001
Ordering factor 2.9 (3.0) 2.8 (2.9) 3.1 (3.1) 0.614
Neutralising factor 2.4 (3.0) 2.0 (2.6) 2.8 (3.3) 0.133
Washing factor 1.8 (2.4) 1.5 (2.1) 2.2 (2.8) 0.137
p Significance indicates the Stuedent’s t test comparison between clozapine monotherapy and poly-pharmacy groups.
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own thoughts’. In turn, some positive symptoms of schizophrenia
might lead to patient’s repetitive behaviour (Faragian et al. 2009),
so we explored the effect of psychosis on the OCI-R sub-scales.
In the monotherapy sub-sample, psychosis severity (measured
with CGI-positive symptoms score) significantly correlated with
total OCI-R (r = 0.38; p = 0.002) and obsessing factor (r = 0.59;
p < 0.001) but not with checking behaviour factor (r = 0.17; p =
0.18). Similar results were seen in the poly-medicated group,
where psychosis significantly correlated with total OCI-R (r =
0.32; p = 0.018) and obsessing factor (r = 0.46; p < 0.001) but not
checking factor (r = 0.20; p = 0.15).
We further explored the role of psychosis by dividing the
118 cases into those with positive symptoms (GCI-positive symp-
toms >1; n = 84) and those with complete psychosis remission
(GCI-positive symptoms = 1; n = 34). Patients with active psych-
osis presented a significantly higher total OCI-R score (22.5 S.D.
= 13.5 v. 14.8 S.D. = 10.9; t = 2.955; p = 0.004) and higher obsessing
factor (5.9 S.D.= 3.5 v. 2.3 S.D. = 2.5; t = 5.277; p < 0.001) but not
checking factor (5.4 S.D. = 3.7 v. 4.3 S.D. = 3.2; t = 1.542; p =
0.126). The result made us consider positive symptoms severity
as a confounding factor that should be taken into consideration
in subsequent analyses.
Factors associated with OCD
We assessed length of clozapine treatment and degree of cloza-
pine exposure as risk factors for OCD onset, as both have been
described in the literature (Lin et al. 2006; Boyette et al. 2011;
Schirmbeck et al. 2011; Scheltema Beduin et al. 2012).
In our sample, length of clozapine treatment significantly corre-
lated with checking severity (r = 0.21; p = 0.026), but not with total
OCI-R (r = 0.15; p = 0.10) or obsessing factor (r = 0.02; p = 0.86).
A partial correlation of length of treatment and checking factor,
controlled by psychosis severity, showed a stronger correlation
(r = 0.25; p = 0.006). Figure 2 plots length of clozapine treatment
and significant checking and obsessing factors (cut-off point ⩾5).
With regard to the influence of clozapine dose on OCD, we con-
trolled for three confounders that have not been considered together
before: (i) clozapine plasma levels, as dose is markedly influenced by
pharmacokinetic factors (i.e. smoking) (Couchman et al. 2010); (ii)
poor compliance with medication, which can be irregular so we
used the plasmaclozapine:norclozapine ratio, as it is a proxy for com-
pliance (Couchman et al. 2010) and (iii) as in our sample, positive
symptoms significantly correlated with clozapine dose (r = 0.22;
p = 0.015) and plasma levels (r = 0.25; p = 0.007), we used partial cor-
relation to co-variate for psychosis severity.
Therefore, for this analysis, we included cases on monother-
apy, with no change in dose or smoking habit during the prior
3 months and showing adequate medication compliance, mea-
sured as clozapine:norclozapine ratio between 0.5 and 1.0, to a
final sample of 37. Table 3 shows the direct correlation between
OCS and clozapine dose and plasma levels as well as partial cor-
relation of these parameters controlling for psychosis.
Discussion
In our study, with the largest sample studied so far, about half of
the 118 cases of clozapine-treated schizophrenia patients reported
OCD measured with the OCI-R. Crucially, we were able to iden-
tify the distinct risk factors associated with the two main OCD
subscales. Checking compulsions, the most prevalent group of
symptoms, were associated with the length of clozapine treatment,
whereas obsessions, the second most common group of symp-
toms, were associated with psychosis severity. None of the symp-
toms were associated with clozapine dose or plasma level.
The British National Formulary still considers OCD as a rare
(one out of 10 000) clozapine side effect. In our sample, the
OCS prevalence was 47%, a mid-point between 5% and 74%
(de Haan et al. 1999; Lin et al. 2006; Mahendran et al. 2007;
Mukhopadhaya et al. 2009; Schirmbeck et al. 2011) among the
Fig. 1. Percentage of significant (cut-off point of 5) of the six OCI-R factors, in the total sample (dark grey), monotherapy (light grey) and poly-pharmacy (black)
groups.
Fig. 2. Percentage of significant ‘obsessive’ and ‘checking behaviour’ using the OCI-R
factor and a five-point cut-off threshold and length of clozapine treatment in 5-year
intervals.
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reported ranges in clozapine-treated patients. This prevalence is
three times the OCD prevalence in non-clozapine patients
(Swets et al. 2014) and suggests a stronger effect in clozapine-
treated patients. To limit a potential prevalence overestimation,
we used a 21-point cut-off for OCD diagnosis, instead of the
less restrictive 18 points suggested by OCI-R (Foa et al. 2002).
Consistent with previous reports (Guillem et al. 2009), we also
found a higher prevalence in the poly-medicated and more severe
cases (64%) compared with those with monotherapy (31%). In
summary, our results might help to raise awareness of OCD in
clozapine-treated patients among clinicians.
Importantly, independent OC factors were adequately mea-
sured with the OCI-R, as seen in the contrast of the six-factor
structure in our sample and the original OCI-R validation (Foa
et al. 2002), which is relevant taking into account it is a self-rated
scale. This is in line with prior factor analyses using Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) (Goodman et al. 1989)
where the same five-factor structure was found in 51 cases of
antipsychotic-induced OCD (Kim et al. 2012) and in 110 cases
of comorbid OCD in schizophrenia (Faragian et al. 2009). Our
findings support the use of standardised OCD symptom scales
in clinical settings for screening and monitoring of OCS in this
population (Doyle et al. 2014; Swets et al. 2014).
Clinically, we found a shift towards predominantly compulsive
behaviours after prolonged (a decade) treatment with clozapine.
Checking was the most prevalent OCD symptom with half of
patients reporting significant distress, which is consistent with
prior studies in both clozapine- (Kim et al. 2012) and
non-clozapine-treated (Faragian et al. 2009) patients. In our sam-
ple, checking gradually increased over time (Fig. 2), with 29%
prevalence among the cases with <5 years of treatment to 69%
in those with more than 20 years of treatment. This replicates
prior reports (Lin et al. 2006; Boyette et al. 2011; Schirmbeck
et al. 2011; Scheltema Beduin et al. 2012) associating longer clo-
zapine exposure to more checking compulsion.
We also found that obsessing was associated with severity of
positive symptoms, but not with treatment duration or clozapine
dose/plasma level. Our results replicate prior studies using
Y-BOCS that shown a specific correlation between delusion sever-
ity and obsessions (Guillem et al. 2009; Sa et al. 2009). A study
also using OCI-R (Kumbhani et al. 2010) did not report a correl-
ation, but included only 29 patients on full remission of psychosis,
which can account for the difference in the findings.
Nevertheless, discerning whether an unwanted thought is an
obsession or a delusion with partial insight in a patient with active
psychosis can be on occasion clinically challenging but also
relevant for treatment decisions (Leung & Palmer, 2016). Of
note, these conceptual debates are not exclusive to schizophrenia.
For instance, the distinction of whether specific repetitive behav-
iour represents complex tics or compulsions in Tourette disorder
have been studied (Kim et al. 2012) and about 20% of cases pre-
sent both symptoms at the same time. For our study, we decided a
pragmatic approach, measuring both phenomena independently,
whereas others have excluded subjects, in whom OCD symptoms
might be attributed to psychotic experience (Poyurovsky et al.
2001; Poyurovsky et al. 2004). The OCI-R factor structure in
our sample mimics the six factors structure in pure OCD cases,
and therefore we are relatively confident that the obsessing factor
was adequately measured. However, further study of the overlap-
ping phenomenology is required.
To date, no studies had found a direct correlation between clo-
zapine plasma levels and OCD symptoms or severity. In one study
of 26 patients on clozapine monotherapy (Schirmbeck et al.
2011), a correlation of OCD severity with dose, but not plasma
levels was found. Significantly, dose is not an accurate measure
of exposure to clozapine, as this is also influenced by compliance
or pharmacokinetic factors. Another study showed that clozapine
schizophrenia patients with OCD had higher clozapine plasma
levels (Lin et al. 2006). However, this study did not account for
other pharmacological interactions as clozapine patients with
OCD group were treated with fluvoxamine, an antidepressant
for OCD that significantly increases clozapine plasma levels
(Couchman et al. 2010). Finally, none of these studies controlled
for psychosis severity, which in our sample strongly correlated
with clozapine dose. We initially found a direct bivariate correl-
ation between plasma levels and obsessing and checking behav-
iour. However, this correlation became non-significant when
controlled by level of psychosis (see Table 3), suggesting that
severity of positive symptom could be a confounding factor.
Nevertheless, the absence of correlation of clozapine dose and
OCD in our study should be considered cautiously as these results
relied on a cross-sectional evaluation. Indeed, some previous find-
ings also pointed to OCD improvement after clozapine reduction
or withdrawal (Englisch et al. 2009; Leung & Palmer, 2016). A
potential explanation would be that OCD symptoms were trig-
gered by a high clozapine dose. If the dose was later reduced
due to other factors (i.e. sedation or metabolic side effects), we
would not have seen a correlation in our study. A long-term
follow-up study before and after clozapine would help to under-
stand this particular aspect.
The pathophysiological mechanisms of clozapine-induced
OCD are beginning to be elucidated. Recent studies support a
Table 3. Correlation of clozapine dose, plasma levels and norclozapine v. total OCI-R score and obsessing and checking factor in 37 cases on clozapine
monotherapy and adequate compliance
Direct correlation Correlation mediated by positive symptoms
Clozapine
dose
Clozapine
plasma level
Norclozapine
plasma levels
Clozapine
dose
Clozapine
plasma level
Norclozapine
plasma levels
OCI-R total score R = 0.14;
p = 0.40
R = 0.29;
p = 0.08
R = 0.25;
p = 0.14
R =−0.02;
p = 0.89
R =−0.06;
p = 0.71
R =−0.11;
p = 0.54
Obsessing factor R = 0.18;
p = 0.28
R = 0.46;
p = 0.004
R = 0.37;
p = 0.024
R = 0.09;
p = 0.60
R = 0.22;
p = 0.19
R = 0.25;
p = 0.14
Checking factor R =−0.01;
p = 0.96
R = 0.33;
p = 0.048
R = 0.29;
p = 0.08
R = 0.10;
p = 0.57
R = 0.18;
p = 28
R = 22;
p = 0.19
First using bivariate correlation and then a partial correlation mediated by psychosis severity.
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biological plausibility based on similarities in cognitive deficits
(Patel et al. 2010; Schirmbeck et al. 2011), brain circuits
(Schirmbeck et al. 2015) and genetic variants (Kwon et al.
2009) to those with pure OCD. Specifically, similarly to pure
OCD patients, clozapine-treated schizophrenia patients with
OCD consistently showed abnormal impulse inhibition, a ten-
dency to response perseveration and difficulties in set-shifting
abilities (Patel et al. 2010; Schirmbeck et al. 2011) associated
with abnormal activation of orbitofrontal cortex (Schirmbeck
et al. 2015) and linkage with significant variants of the SLC1A1
gene (Kwon et al. 2009).
The nature of the compulsive symptoms arising from chronic
clozapine treatment, with its predominance in checking compul-
sion and obsessions, is a relevant observation. We would like to
hypothesise a cognitive interpretation. In our sample, the two
symptoms were associated with distinct risk factors: ‘obsessing’
correlated with positive symptoms and ‘checking’ with longer
treatment. We suggest that abnormal habitual v. goal-directed
behavioural control might be a coherent explanation as it inte-
grates the content of psychotic symptoms and clozapine’s mechan-
ism of action. Briefly, the abnormal habit-formation model posits
that OCD might result from an imbalance between excessive for-
mation of stimulus–response associations and a diminished ability
for goal-directed actions (Gillan et al. 2016). Thus, repetition in
the context of a diminished ability for consideration of action out-
come, leads to automatisation of behaviour. Indeed, schizophrenia
patients exhibit deficits in goal-directed actions, likely representing
a failure of cortical control over striatum (Morris et al. 2015),
which might also increase vulnerability to OCD.
Using this conceptual framework, our hypothetical model sug-
gests two OCD stages in clozapine-treated schizophrenia patients.
Initially, goal-directed checking behaviour would be driven by
psychosis (i.e. checking due to delusional hypervigilance). Then,
a second phase characterised by ‘obsessions’ ameliorated by cloza-
pine treatment but with a persisting (habitual) repetitive checking
behaviour. A plausible mechanism for the persistence of repetitive
behaviour would be clozapine’s antagonism of 5-HT2A and 5-HT2C
receptors (Schirmbeck & Zink, 2012). Decrease in serotonin neuro-
transmission in the brain causes perseveration in reversal learning
tasks, the hallmark of cognitive inflexibility in compulsive beha-
viours including OCD (Robbins et al. 2012). For instance, in non-
human primates, selective reduction in prefrontal serotonin is asso-
ciated with cognitive inflexibility (Clarke et al. 2004). Similarly in
rodents either reduction of 5-HT2A binding in the orbitofrontal
cortex (Barlow et al. 2015) or 5-HT2A receptor antagonism
(Boulougouris et al. 2008) is associated with impaired reversal
learning. In humans, a dietary tryptophan depletion (a technique
that acutely reduces serotonin in the brain) promotes habitual
over goal-directed control (Worbe et al. 2015) and affects goal-
directed learning (Worbe et al. 2016). Moreover, schizophrenia
patients on clozapine who develop OCD present selective persever-
ation, as seen in the extra-dimensional set-shifting task (Patel et al.
2010). Taken together, these results suggest several plausible
mechanisms such as impaired cognitive flexibility, impaired goal-
directed behavioural control and reliance on habits by which cloza-
pine antagonism to serotonin receptors might induce repetitive
behaviour. This, our model integrates not only the present results
but also the results of previous studies (Lin et al. 2006; Boyette
et al. 2011; Schirmbeck et al. 2011; Scheltema Beduin et al. 2012;
Schirmbeck & Zink, 2012) and patients’ narratives. Others have
described that non-clozapine patients present a profile charac-
terised by higher contamination obsessions and washing
compulsions (Krüger et al. 2000; Faragian et al. 2009), consistent
with the proposed model of abnormal habit formation.
There are limitations to our study. The first limitation is the
inability to replicate our findings experimentally on healthy volun-
teers. As a drug with potentially lethal side effects, clozapine cannot
be tested in healthy volunteers and it is only available for severe
cases of schizophrenia, which limits experimental studies in
humans. Second, despite that our sample is the largest studied to
date, due to the complexity of the disorder, the amount of con-
founding factors and the staged approach proposed, a replication
using an even larger sample is warranted. Additionally, this was a
cross-sectional study, whereas a prospective design would address
some of limitations of our approach such as the specific time of
onset of checking behaviour. However, the feasibility of such
study might be compromised by the fact that we found that
OCD prevalence increased only after 10 years treatment with the
same medication. Finally, OCD symptoms were evaluated using a
self-rated scale and the study might benefit of replication using a
clinician-rated scale such as Y-BOCS. However, we found that the
responses followed the five-factor structure, suggesting that the
answers were, at least, similar to other population such as OCD
patients. There are some other inherent limitations related to the
current diagnostic classification, as perhaps using two distinct noso-
logic categories (schizophrenia and OCD) does not fully capture or
explain the phenomena. In line with the recent National Institute of
Mental Health (NIHM) Research Domain Criteria (RDoC) initia-
tive (Insel, 2014), checking behaviour in clozapine-treated patients
might be better characterised in schizophrenia patients as a
drug-enhanced habit, possibly mediated by the striatum.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S003329171800017X
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